Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

55X_ROI_Q1_2026 Aug. 15 at 7:04 PM

$SLS VIALE- M $ABBV Aza+VEN Phase 3 Trial for AML First Remission (CR1) Mainteance. Aza+VEN is the so called BAT for the SLS Phase 3 Second Remission (CR2) Control Arm Patients. 8 Statistical Analysis Plan Modifications - attempting to find a Safe Dosing Schedule, and a OS/RFS Endpoint that was quietly removed from the P3 in Version 5.0 - they Gave up on A Survival Benefit beyond Onureg -- SOC -- which had a MOS of 24.7 Months - GPS P2 in this same Setting was > 67.6 months. $XBI $GLSI

0 · Reply

BioTechHealthX Aug. 15 at 5:23 PM

$ABBV AbbVie stock is entering its post-Humira era with Skyrizi and Rinvoq driving growth. See why analysts still view ABBV as a healthcare stock worth watching in 2026. https://biotechhealthx.com/biotech-news/could-abbvie-abbv-be-one-of-the-best-healthcare-stocks-to-buy-and-hold/

0 · Reply

GordoHLYK13 Aug. 15 at 7:58 AM

$IGC That’s a 6-year-old, fully resolved SEC matter—not a current investigation or operational issue. The business has completely transformed from its 2020 infrastructure/cannabis roots into IGC Pharma, a clinical-stage biotech focused on Alzheimer’s. Today, the story is Phase 2 CALMA, IGC-AD1, and the upcoming Q4 2026 data—not recycled 2020 paperwork. Bringing up ancient, settled filings to create fresh fear is noise. Watch the clinical data, not the archives. $IGC 🚀📈 $PFE $ABBV $MRNA Shorts are digging deep for old narratives—looks like fear is building ahead of IGC’s Phase 2 results. The closer we get to the data, the louder the noise gets. $IGC 🚀📈

1 · Reply

55X_ROI_Q1_2026 Aug. 14 at 10:42 PM

$SLS $ABBV $SLS 80,000 AML Patients Diagnosed Annually 80% Make it into Remission / 50,000+ Each Year

0 · Reply

Oldpuck Aug. 14 at 8:48 PM

$ABBV Payday 👏👏

0 · Reply

leifstocks Aug. 14 at 8:32 PM

Recaps $PLTR +317% | $TSLL +200% $DCBO +157% | $ABBV +153% No full-port. No chasing. Just wait for setup, manage risk, take profit. Sharing the full process daily. NFA

0 · Reply

55X_ROI_Q1_2026 Aug. 14 at 6:15 PM

$SLS Not Sure if People here are aware: Gps Phase 2 Combination Data with $MRK is much better than SOC< Elahere - which $ABBV bought for $10B ... Mrk Dr. Cohen in co-authoring the published data, recommended a Phase 3 for Remission Maintenance - she said it work even better - in a macroscopic setting. and they(mrk) like all of us have been Waiting... and now - 78 Events 95 Days Ago ... we are finally going to Get the Final Results. Bottom Line: GPS is announcing Phase 3 Results that are worth 25X the Current Market Cap.

0 · Reply

55X_ROI_Q1_2026 Aug. 14 at 5:34 PM

$SLS $100K Invested here today could easily be ... easily be, $1M to $2.5M --- absolutely -- When the P3 REGISTRATIONAL Results/FDA GREEN LIGHT are IN, which Literally is going to be ANY DAY Now - it's Day 95 since the 78th ... in addition to 20 differenct cancer Types, WT1 + Cancer is Ubiquitously expressed on AML Cancer Cells, REGARDLESS of Mutation, DNMTA, Runx1, KMT2a, NMP1/2 IDH1/2 FLT3 TP53 ASXL+ SRFz2 --- all AML .... Ubiquitously --- ALL AML --- Universal Immunotherapy for AML remission maintenance and beyond. We already have P2 Data with MRK for Ovarian Cancer that is Much better than Elahere, theSOC that $ABBV bought for $10B.... Wake up.

0 · Reply

GoforProMIS Aug. 14 at 5:26 PM

$PMN new PT from Guggenheim raised to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $MRK $RHHBY $ABBV

0 · Reply

LUXtrades0 Aug. 14 at 4:57 PM

$ABBV 🩺 $255 14 AUG 26 (W) CALL 100 $0.85 ➡️ $2.10 🤑 147% GAINER! LIKE THIS POST AND TURN MY POST NOTIFICATIONS ON 🤾🏼‍♂️

0 · Reply

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD JNJ LLY MRK

Aug 4, 2026, 8:00 AM EDT - 11 days ago

Market Cap	443.15B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	22.89
Forward PE	17.68
Profit Margin	6.91%
Debt to Equity Ratio	-12.03

Volume	4,195,300
Avg Vol	7,011,926
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	59%
Beta	0.30
Analysts	Strong Sell
Price Target	$274.59